Global Polycystic Kidney Disease Drugs Market 2019-2023

多発性嚢胞腎疾患薬の世界市場2019-2023

◆タイトル:Global Polycystic Kidney Disease Drugs Market 2019-2023
◆商品コード:IRTNTR31525
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年6月17日
◆ページ数:125
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、多発性嚢胞腎疾患薬の世界市場について調べ、多発性嚢胞腎疾患薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、多発性嚢胞腎疾患薬の市場規模をセグメンテーション別(種類別(ADPKD、ARPKD)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は多発性嚢胞腎疾患薬の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・多発性嚢胞腎疾患薬の市場状況
・多発性嚢胞腎疾患薬の市場規模
・多発性嚢胞腎疾患薬の市場予測
・多発性嚢胞腎疾患薬の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(ADPKD、ARPKD)
・多発性嚢胞腎疾患薬の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

Global Polycystic Kidney Disease Drugs Market: About this market

Polycystic kidney disease is a genetic disorder in which clusters of cysts develop primarily within the kidneys, causing kidneys to enlarge and lose function over time. Technavio’s polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD). Our analysis also considers the sales of polycystic kidney disease drugs in North America, Europe, Asia, and ROW. In 2018, the ARPKD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of the disease will play a significant role in the ARPKD segment to maintain its market position. Our global polycystic kidney disease drugs market report looks at factors such as the high prevalence of chronic kidney diseases, special regulatory designations, and the increasing R&D for developing new drugs. However, the lack of approved drugs, availability of substitute treatment options, and stringent regulations may hamper the growth of the polycystic kidney disease drugs industry over the forecast period.

Global polycystic kidney disease drugs market: Overview

Special regulatory designations

The growing focus on developing and evaluating drugs that effectively cure and diagnose rare diseases is encouraging organizations such as the US FDA and EMA to provide special regulatory designations to underlying companies. This provides companies with benefits such as tax credits for clinical trials and protocol assistance. These designations help vendors to easily launch drugs, which will help them in generating revenues. Thus, the special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.

Favorable reimbursement policies

The high cost of off-label drugs and the approved novel drug for the treatment of polycystic kidney disease makes it challenging for patients to afford it. Hence, government and non-government organizations are introducing reimbursement policies to help patients in availing the treatment. These policies are further encouraging vendors to increase investments in R&D. Thus, the presence of favorable reimbursement policies will fuel the growth of the market.

For the detailed list of factors that will drive the global polycystic kidney disease drugs market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global polycystic kidney disease drugs market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic kidney disease drugs providers, that include Johnson & Johnson Services Inc., Merck & Co., Inc., Otsuka Holdings Co. Ltd., Reata Pharmaceuticals Inc., and Sanofi.

Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

ADPKD – Market size and forecast 2018-2023

ARPKD – Market size and forecast 2018-2023

Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

Increasing research funding

Favorable reimbursement policies

Growing awareness about kidney diseases

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Johnson & Johnson Services Inc.

Merck & Co., Inc.

Otsuka Holdings Co. Ltd.

Reata Pharmaceuticals Inc.

Sanofi

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Some of the clinical stage drugs for polycystic kidney disease

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: ADPKD – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: ADPKD – Year-over-year growth 2019-2023 (%)

Exhibit 22: ARPKD – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: ARPKD – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by type

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Prevalence of chronic kidney diseases per 100 people

Exhibit 43: Impact of drivers and challenges

Exhibit 44: Vendor landscape

Exhibit 45: Landscape disruption

Exhibit 46: Vendors covered

Exhibit 47: Vendor classification

Exhibit 48: Market positioning of vendors

Exhibit 49: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 50: Johnson & Johnson Services Inc. – Business segments

Exhibit 51: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 52: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 53: Johnson & Johnson Services Inc. – Segment focus

Exhibit 54: Johnson & Johnson Services Inc. – Key offerings

Exhibit 55: Johnson & Johnson Services Inc. – Key customers

Exhibit 56: Merck & Co. Inc. – Vendor overview

Exhibit 57: Merck & Co. Inc. – Business segments

Exhibit 58: Merck & Co. Inc. – Organizational developments

Exhibit 59: Merck & Co. Inc. – Geographic focus

Exhibit 60: Merck & Co. Inc. – Segment focus

Exhibit 61: Merck & Co. Inc. – Key offerings

Exhibit 62: Merck & Co. Inc. – Key customers

Exhibit 63: Otsuka Holdings Co. Ltd. – Vendor overview

Exhibit 64: Otsuka Holdings Co. Ltd. – Business segments

Exhibit 65: Otsuka Holdings Co. Ltd. – Organizational developments

Exhibit 66: Otsuka Holdings Co. Ltd. – Geographic focus

Exhibit 67: Otsuka Holdings Co. Ltd. – Segment focus

Exhibit 68: Otsuka Holdings Co. Ltd. – Key offerings

Exhibit 69: Otsuka Holdings Co. Ltd. – Key customers

Exhibit 70: Reata Pharmaceuticals Inc. – Vendor overview

Exhibit 71: Reata Pharmaceuticals Inc. – Organizational developments

Exhibit 72: Reata Pharmaceuticals Inc. – Key offerings

Exhibit 73: Reata Pharmaceuticals Inc. – Key customers

Exhibit 74: Sanofi – Vendor overview

Exhibit 75: Sanofi – Business segments

Exhibit 76: Sanofi – Organizational developments

Exhibit 77: Sanofi – Geographic focus

Exhibit 78: Sanofi – Segment focus

Exhibit 79: Sanofi – Key offerings

Exhibit 80: Sanofi – Key customers

Exhibit 81: Validation techniques employed for market sizing

Exhibit 82: Definition of market positioning of vendors



【掲載企業】

Johnson & Johnson Services Inc.
Merck & Co., Inc.
Otsuka Holdings Co. Ltd.
Reata Pharmaceuticals Inc.
Sanofi.

★調査レポート[多発性嚢胞腎疾患薬の世界市場2019-2023] (Global Polycystic Kidney Disease Drugs Market 2019-2023 / IRTNTR31525)販売に関する免責事項
[多発性嚢胞腎疾患薬の世界市場2019-2023] (Global Polycystic Kidney Disease Drugs Market 2019-2023 / IRTNTR31525)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆